LC-MS/MS를 이용한 혈청 중 finasteride 분석
Determination of finasteride in human serum by LC-MS/MS
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
본 연구는 LC-ESI-MS/MS를 이용하여 혈청 중의 피나스테라이드의 분석법을 확립하고, 밸리데이션을 통하여 분석방법의 타당도를 검증하였다. 혈청에 내부표준물질로 베클로메타손을 첨가한 후 methyl tert-butyl ether (MTBE)을 사용하여 액체상추출법(liquid-liquid extraction, LLE)으로 전처리하였다. LC-MS/MS의 양이온 모드에서 피나스테라이드와 베클로메타손의 MRM (multiple reaction monitoring) mass transition은 각각 m/z 373.2→305.2, m/z 409.3→391.2 이었으며, 머무름 시간은 각각 5.81분, 5.46분이었다. 피나스테라이드의 정량한계는 0.1 ng/mL로 나타났으며, 0.1~20.0 ng/mL의 농도 범위에서 검량선은 우수한 직선성(R^2=0.9997)을 확인할 수 있었으며, 회수율은 80~83% 범위이었다. 피나스테라이드의 일내에 대한 정밀도는 6.3~10.6%, 정확도는 97.3~103.6% 범위이었으며, 연속 3일간 수행한 일간 정밀도는 0.8~5.2%,정확도는 99.8~102.5%로 나타났다.
Abstract
A liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS) method was developed and validated for the determination of finasteride in human serum. Beclomethasone was used as internal standard (IS) and liquid-liquid extraction (LLE) using methyl tert-butyl ether (MTBE) was carried out to isolate analyte. The mass transitions monitored in multiple reaction monitoring (MRM) in positive ion mode were m/z 373.2→305.2 for finasteride and m/z 409.3→391.2 for IS. Retention times of finasteride and IS were 5.81 and 5.46 min, respectively. The limit of quantitation (LOQ) was 0.1 ng/mL and the calibration curve showed good linearity in the range of 0.1~20.0 ng/mL (R^2=0.9997). The intra-day assay precision and accuracy were in the range 6.3~10.6% and 97.3~103.6%, respectively, and the inter-day assay precision and accuracy were in the range 0.8~5.2% and 99.8~102.5%, respectively. The sample extract recovery of the method was 80~83%.
참고문헌 (21)
- H. A. Guess, , Prostate, 17, pp.241~246 (1990)
- T. Liang, , Endocrinology, 177, pp.571~579 (1985)
- J. R. Brooks, , Steroids, 47, pp.1~19 (1986)
- D. H. Peters, , Drugs, 46, pp.177~208 (1993)
- M. I. Wilde, , Drugs, 57, pp.557~581 (1999)
- K. J. McClellan, , Drugs, 57, pp.111~126 (1999)
- S. Rossi, "Australian Medicines Handbook" (2004)
- "Blood Guidances" (2011), Food and Drug Administration
- "Blood Regulation Law" (2011), Ministry of Health and Welfare
- T. Takano, , J. Chromatogr., B, 676, pp.141~146 (1996)
- P. Ptáèek, , J. Chromatogr., B, 738, pp.305~310 (2000)
- A. I. Segall, , J. Liquid Chromatogr. Related Technol, 25, pp.3167~3176 (2002)
- G. Carlucci, , J. Chromatogr., B, 693, pp.245~248 (1997)
- X. Li, , Acta Pharmaceutica Sinica, 38(6), pp.455~457 (2003)
- F. Q. Guo, , J. Pharm. Biomed. Anal, 43, pp.1507~1513 (2007)
- X. Chen, , J Chromatogr Sci, 46(4), pp.356~361 (2008)
- M. L. Constanzer, , J. Chromatogr. B, 658, pp.281~287 (1994)
- B. K. Matuszewski, , Eng, Anal. Chem, 70, pp.882~889 (1998)
- A. Guarna, , J. Chromatogr. B, 674, pp.197~204 (1995)
- "Bioanalytical Method Validation" (2009), National Institute of Food and Drug Safety Evaluation
- "Guidance for Industry, Bioanalytical Method Validation" (2001), Food and Drug Administration